{
    "2020-01-13": [
        [
            {
                "time": "2018-01-02",
                "original_text": "Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "stock sinks",
                        "market gains"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2020-01-03",
                "original_text": "Top Pharmaceutical Stocks for Q1 2020",
                "features": {
                    "keywords": [
                        "top pharmaceutical stocks",
                        "Q1 2020"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2020-04-15",
                "original_text": "Is Pfizer (PFE) Stock Outpacing Its Medical Peers This Year?",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "outpacing",
                        "medical peers"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-07-20",
                "original_text": "Glaxo Files Marketing Application for Fostemsavir in Europe",
                "features": {
                    "keywords": [
                        "Glaxo",
                        "marketing application",
                        "Fostemsavir",
                        "Europe"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2020-01-10",
                "original_text": "In time for biotech's biggest conference, Union Square costs climb",
                "features": {
                    "keywords": [
                        "biotech",
                        "conference",
                        "Union Square",
                        "costs climb"
                    ],
                    "sentiment_score": -0.4,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2020-06-15",
                "original_text": "Nektar Up 25% as Bristol-Myers Expands Bempeg Collaboration",
                "features": {
                    "keywords": [
                        "Nektar",
                        "Bristol-Myers",
                        "Bempeg",
                        "collaboration"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-01-13",
                "original_text": "Benzinga Pro's Top 5 Stocks To Watch For Mon., Jan. 13, 2020: WCC, LULU, XLF, TEAM, BIIB",
                "features": {
                    "keywords": [
                        "Benzinga Pro",
                        "top stocks",
                        "WCC",
                        "LULU",
                        "XLF",
                        "TEAM",
                        "BIIB"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "various"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2020-03-10",
                "original_text": "Biogen to buy from Pfizer an asset to develop into potential Alzheimer's, Parkinson's treatments",
                "features": {
                    "keywords": [
                        "Biogen",
                        "Pfizer",
                        "Alzheimer's",
                        "Parkinson's",
                        "treatments"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-03-10",
                "original_text": "Biogen to Acquire Novel Clinical Stage Asset with Application in Alzheimer’s Disease and Parkinson’s Disease from Pfizer Inc.",
                "features": {
                    "keywords": [
                        "Biogen",
                        "acquire",
                        "clinical stage asset",
                        "Alzheimer’s",
                        "Parkinson’s",
                        "Pfizer"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-05-20",
                "original_text": "Axsome Therapeutics Enters into Exclusive License Agreement with Pfizer Inc. for Pfizer’s Reboxetine Clinical and Nonclinical Data and for New Phase 3 Esreboxetine Product Candidate",
                "features": {
                    "keywords": [
                        "Axsome Therapeutics",
                        "license agreement",
                        "Pfizer",
                        "Reboxetine",
                        "Esreboxetine"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}